At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jul 30, 2026 at 08:30 ET
Disc Medicine reported Q2 2026 net loss of $59.5M ($1.54/share), beating consensus of -$1.77 by 13%. The key catalyst is the completed Type A FDA meeting aligning that the Phase 3 APOLLO trial of bitopertin in EPP, if successful, can serve as the basis for a CRL response, with topline data expected in Q4 2026. The company also completed enrollment for the RESTORE-PV Phase 2 study of DISC-3405, with initial data now expected in Q3 2026, ahead of schedule.
- Q2 2026 net loss of $59.5M ($1.54/share) vs $55.2M ($1.58/share) in Q2 2025, beating consensus of -$1.77
- Cash, cash equivalents, and marketable securities of $717.7M as of June 30, 2026, providing runway into 2029
- Completed Type A meeting with FDA; Phase 3 APOLLO topline data for bitopertin in EPP expected Q4 2026
- Completed enrollment for RESTORE-PV Phase 2 study of DISC-3405 in polycythemia vera; initial data expected Q3 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access